Page 28 - MI-1-1
P. 28

Microbes & Immunity                                      RANTES/CCL5 and ezrin peptide RepG3 for long COVID



            31.  Islam M, Kalita T, Saikia AK, et al. Significance of RANTES-  42.  Monath TP. Treatment of yellow fever.  Antiviral  Res.
               CCR5 axis and linked downstream immunomodulation in   2008;78:116-124.
               Dengue pathogenesis: A study from Guwahati, India. J Med      doi: 10.1016/j.antiviral.2007.10.009
               Virol. 2019;91(12):2066-2073.
                                                               43.  Sakthivel SK, Singh UP, Singh S, Taub DD, Igietseme JU,
               doi: 10.1002/jmv.25561
                                                                  Lillard JW Jr. CCL5 regulation of mucosal chlamydial
            32.  Duma L, Häussinger D, Rogowski M, Lusso P, Grzesiek S.   immunity and infection. BMC Microbiol. 2008;8:136.
               Recognition of RANTES by extracellular parts of the CCR5      doi: 10.1186/1471-2180 8-136
               receptor. J Mol Biol. 2007;365(4):1063-1075.
                                                               44.  Singh R, Singh S, Briles DE, Taub DD, Hollingshead SK,
               doi: 10.1016/j.jmb.2006.10.040
                                                                  Lillard JW Jr. CCL5-independent helper T lymphocyte
            33.  Coenen  M,  Nattermann  J.  The  role  of  CCR5  in  HCV   responses to immuno-dominant pneumococcal surface
               infection. Eur J Med Res. 2010;15:97-101.          protein A epitopes. Vaccine. 2012;30(6):1181-1190.
               doi: 10.1186/2047-783X-15-3-97                     doi: 10.1016/j.vaccine.2011.12.020
            34.  Thio CL, Astemborski J, Thomas R, et al. Interaction between   45.  Vesosky B, Rottinghaus EK, Stromberg P, Turner J, Beamer G.
               RANTES promoter variant and CCR5Delta32 favors recovery   CCL5 participates in early protection against Mycobacterium
               from hepatitis B. J Immunol. 2008;181:7944-7947.   tuberculosis. J Leukoc Biol. 2010;87(6):1153-1165.
               doi: 10.4049/jimmunol.181.11.7944                  doi: 10.1189/jlb.1109742
            35.  Elliott MB, Tebbey PW, Pryharski KS, Scheuer CA, Laughlin   46.  Richardson JP, Moyes DL. Adaptive immune responses to
               TS, Hancock GE. Inhibition of respiratory syncytial virus   Candida albicans infection. Virulence. 2015;6(4):327-337.
               infection with the CC chemokine RANTES (CCL5). J Med      doi: 10.1080/21505594.2015.1004977
               Virol. 2004;73(2):300-308.
                                                               47.  Huang C, Levitz SM. Stimulation of macrophage inflammatory
               doi: 10.1002/jmv.20091
                                                                  protein-1a, macrophage inflammatory protein-1b, and
            36.  Silva T, Temerozo JR, do Vale G,  et al. The chemokine   RANTES by Candida albicans and Cryptococcus neoformans
               CCL5 inhibits the replication of influenza A virus through   in peripheral blood mononuclear cells from persons with
               SAMHD1 modulation.  Front Cell Infect Microbiol.   and without human immunodeficiency virus infection.
               2021;11:549020.                                    J Infect Dis. 2000;181:791-794.

               doi: 10.3389/fcimb.2021.549020                     doi: 10.1086/315250
            37.  Marques RE, Guabiraba R, Del Sarto JL, et al. Dengue virus   48.  Govender Y, Chan T, Yamamoto HS, Budnik B, Fichorova
               requires the CC-chemokine receptor CCR5 for replication   RN. The role of small extracellular vesicles in viral-
               and infection development. Immunology. 2015;145:583-596.  protozoan symbiosis: Lessons from trichomonasvirus in
                                                                  an isogenic host parasite model. Front Cell Infect Microbiol.
               doi: 10.1111/imm.12476
                                                                  2020;10:591172.
            38.  de-Oliveira-Pinto LM, Marinho CF, Povoa TF,  et al.
               Regulation of inflammatory chemokine receptors on blood      doi: 10.3389/fcimb.2020.591172
               T cells associated to the circulating versus liver chemokines   49.  Murphy PM. The molecular biology of leukocyte chemoattractant
               in dengue fever. PLoS One. 2012;7:e38527.          receptors. Annu Rev Immunol. 1994;12:593-633.
               doi: 10.1371/journal.pone.0038527                  doi: 10.1146/annurev.iy.12.040194.003113
            39.  Wuest TR, Carr DJ. The role of chemokines during herpes   50.  Mueller A, Strange PG. Mechanisms of internalization and
               simplex virus-1 infection. Front Biosci. 2008;13:4862-4872.  recycling of the chemokine receptor, CCR5. Eur J Biochem.
                                                                  2004;271:243-252.
               doi: 10.2741/3045
                                                                  doi: 10.1046/j.1432-1033.2003.03918.x
            40.  Vilela  MC,  Lima  GK,  Rodrigues  DH,  et al.  Absence  of
               CCR5 increases neutrophil recruitment in severe herpetic   51.  Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M,
               encephalitis. BMC Neurosci. 2013;14:19.            Sedighi G, Bahar M. The role of JAK-STAT signaling
                                                                  pathway and its regulators in the fate of T helper cells. Cell
               doi: 10.1186/1471-2202-14-19
                                                                  Commun Signal. 2017;15:23.
            41.  Karim R, Tummers B, Meyers C, et al. Human papillomavirus
               (HPV) upregulates the cellular deubiquitinase UCHL1 to      doi: 10.1186/s12964-017-0177-y
               suppress the keratinocyte’s innate immune response. PLoS   52.  Wong M, Fish EN. RANTES and MIP-1a activate stats in T
               Pathog. 2013;9(5)e1003384.                         cells. J Biol Chem. 1998;273(1):309-314.
               doi: 10.1371/journal.ppat.1003384                  doi: 10.1074/jbc.273.1.309


            Volume 1 Issue 1 (2024)                         22                               doi: 10.36922/mi.2474
   23   24   25   26   27   28   29   30   31   32   33